Recruiting

EndoAVF

Sponsor:

California Institute of Renal Research

Code:

NCT04633304

Conditions

CKD Stage 3

CKD Stage 4

CKD Stage 5

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

EndoAVF System for endovascular AV fistula creation

Study Details

Brief summary:

This is an investigator-initiated post-marketing study that will evaluate use of the WaveLinQ system, a new and novel method of fistula creation using a percutaneous method in patients who require the creation of an arteriovenous fistula (AVF).

Conditions

CKD Stage 3

CKD Stage 4

CKD Stage 5

Study ID

NCT04633304

Start date

Dec 15, 2020

Status verified date

Feb, 2023

Completion date

Dec 31, 2023

Anticipated

Primary completion date

Dec 15, 2023

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Male or Female Age of at least 18 years
2. CKD 3 through 5 as measured by GFR 45 and under by MDRD equation on two separate occasions at least 3 months apart.
3. Provide written informed consent using a form that is approved by the Institutional Review Board (IRB) prior to collection of study data or performance of study procedures.
4. Currently not on hemodialysis.
5. Life expectancy of at least one year
6. Meets Anatomical Criteria for EndoAVF creation via pre-procedure Duplex or Venography Vascular anatomy suitable for creation of the AV fistula
7. Willing to comply with the specified follow-up evaluations

Exclusion Criteria:

1. Anatomical exclusion criteria met
2. Thought to need dialysis within 30 days.
3. The subject is in a hypercoagulable state.
4. The subject has known bleeding diathesis.
5. The subject has insufficient cardiac output to support a native fistula in the opinion of the investigator.
6. Known history of active intravenous drug abuse.
7. The subject has a known allergy or hypersensitivity to contrast media which cannot be adequately pre-medicated.
8. The subject has known adverse effects to sedation and/or anesthesia which cannot be adequately pre-medicated.
9. Evidence of active infection on the day of the index procedure (temperature of ≥ 38.0° Celsius and/ or WBC of ≥ 12,000 cells/ μL, if collected).

Study Design

Enrollment

30 participants

Anticipated

Intervention Model

Single group

Primary purpose

Other

Interventions and Outcome Measures

Arms

other: AVF

Single arm study using primary and secondary end points as comperators between subjects.

Interventions

EndoAVF System for endovascular AV fistula creation

AV fistula creation

Primary outcome measure

  • Procedure Success [ Time Frame: Interval of time from access placement until any intervention is undertaken to maintain or re-establish patency - 6 weeks ]

Central Contacts and Locations

Central contacts

Locations

California Institute of Renal Research

Recruiting

Escondido, California, United States, 92027

Contacts

Principal Investigator:

Osman Khawar, MD

More Information

Sponsor

California Institute of Renal Research

Last update posted

Feb 9, 2023

Last verified

Feb, 2023

Keywords

  • CKD

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by California Institute of Renal Research on 2023-02-09.